Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes

BACKGROUND: Treatment-emergent neuroendocrine prostate cancer (NEPC) after androgen receptor (AR) targeted therapies is an aggressive variant of prostate cancer with an unfavorable prognosis. The underlying mechanisms for early neuroendocrine differentiation are poorly defined and diagnostic and pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Shu, Zhao, Jinge, Lombard, Alan P., D’Abronzo, Leandro S., Leslie, Amy R., Sharifi, Masuda, Lou, Wei, Liu, Chengfei, Yang, Joy C., Evans, Christopher P., Corey, Eva, Chen, Hong-Wu, Yu, Aiming, Ghosh, Paramita M., Gao, Allen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492734/
https://www.ncbi.nlm.nih.gov/pubmed/36159187
http://dx.doi.org/10.1038/s43856-022-00182-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492734/
https://www.ncbi.nlm.nih.gov/pubmed/36159187
http://dx.doi.org/10.1038/s43856-022-00182-9

Ejemplares similares